Cargando…
Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment
Cardiovascular diseases (CVDs) lead to higher morbidity and mortality in rheumatoid arthritis; thus, we aimed to determine whether patients who had discontinued methotrexate treatment before the study enrollment (group MTX 0) were at a higher risk of CVD than patients treated with methotrexate at th...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602828/ https://www.ncbi.nlm.nih.gov/pubmed/34803668 http://dx.doi.org/10.3389/fphar.2021.703279 |
_version_ | 1784601643086512128 |
---|---|
author | Hloch, Karel Doseděl, Martin Duintjer Tebbens, Jurjen Žaloudková, Lenka Medková, Helena Vlček, Jiří Soukup, Tomáš Pávek, Petr |
author_facet | Hloch, Karel Doseděl, Martin Duintjer Tebbens, Jurjen Žaloudková, Lenka Medková, Helena Vlček, Jiří Soukup, Tomáš Pávek, Petr |
author_sort | Hloch, Karel |
collection | PubMed |
description | Cardiovascular diseases (CVDs) lead to higher morbidity and mortality in rheumatoid arthritis; thus, we aimed to determine whether patients who had discontinued methotrexate treatment before the study enrollment (group MTX 0) were at a higher risk of CVD than patients treated with methotrexate at the time of the data collection (group MTX 1). A retrospective, prospective, observational, cross-sectional study was conducted. A total of 125 patients were enrolled in the study. Patients from the MTX 0 group (n = 35) were not treated with methotrexate for 7.54 (SD ± 4.21) years in average. Medical documentation as well as information taken in patient examinations during regular rheumatologist visits was used to obtain the required data. The composite of any CVD occurred less frequently in patients in the MTX 1 group than in the MTX 0 group (18.8 vs. 40.0%, OR 0.35, 95% CI, 0.15 to 0.83; p = 0.017) with a non-significant trend after adjustment for other treatments, which differed between study groups at the baseline (p = 0.054). Significant difference was found for the reduction of myocardial infarction in the MTX 1 group compared to the MTX 0 group (3.5 vs. 14.3%, OR 0.22, 95% CI, 0.05 to 0.97; p = 0.046). There were 4 deaths (4.7%) in the MTX 1 group as compared with 7 (20.0%) in the MTX 0 group (OR 0.20, 95% CI, 0.05 to 0.73; p = 0.015). Our results demonstrate that patients who discontinued methotrexate treatment are at a significantly higher risk of CVD and all-cause mortality. Based on our findings, we recommend stricter control of CVD in cases of methotrexate discontinuation. |
format | Online Article Text |
id | pubmed-8602828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86028282021-11-20 Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment Hloch, Karel Doseděl, Martin Duintjer Tebbens, Jurjen Žaloudková, Lenka Medková, Helena Vlček, Jiří Soukup, Tomáš Pávek, Petr Front Pharmacol Pharmacology Cardiovascular diseases (CVDs) lead to higher morbidity and mortality in rheumatoid arthritis; thus, we aimed to determine whether patients who had discontinued methotrexate treatment before the study enrollment (group MTX 0) were at a higher risk of CVD than patients treated with methotrexate at the time of the data collection (group MTX 1). A retrospective, prospective, observational, cross-sectional study was conducted. A total of 125 patients were enrolled in the study. Patients from the MTX 0 group (n = 35) were not treated with methotrexate for 7.54 (SD ± 4.21) years in average. Medical documentation as well as information taken in patient examinations during regular rheumatologist visits was used to obtain the required data. The composite of any CVD occurred less frequently in patients in the MTX 1 group than in the MTX 0 group (18.8 vs. 40.0%, OR 0.35, 95% CI, 0.15 to 0.83; p = 0.017) with a non-significant trend after adjustment for other treatments, which differed between study groups at the baseline (p = 0.054). Significant difference was found for the reduction of myocardial infarction in the MTX 1 group compared to the MTX 0 group (3.5 vs. 14.3%, OR 0.22, 95% CI, 0.05 to 0.97; p = 0.046). There were 4 deaths (4.7%) in the MTX 1 group as compared with 7 (20.0%) in the MTX 0 group (OR 0.20, 95% CI, 0.05 to 0.73; p = 0.015). Our results demonstrate that patients who discontinued methotrexate treatment are at a significantly higher risk of CVD and all-cause mortality. Based on our findings, we recommend stricter control of CVD in cases of methotrexate discontinuation. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8602828/ /pubmed/34803668 http://dx.doi.org/10.3389/fphar.2021.703279 Text en Copyright © 2021 Hloch, Doseděl, Duintjer Tebbens, Žaloudková, Medková, Vlček, Soukup and Pávek. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Hloch, Karel Doseděl, Martin Duintjer Tebbens, Jurjen Žaloudková, Lenka Medková, Helena Vlček, Jiří Soukup, Tomáš Pávek, Petr Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment |
title | Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment |
title_full | Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment |
title_fullStr | Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment |
title_full_unstemmed | Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment |
title_short | Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment |
title_sort | higher risk of cardiovascular diseases in rheumatoid arthritis patients without methotrexate treatment |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602828/ https://www.ncbi.nlm.nih.gov/pubmed/34803668 http://dx.doi.org/10.3389/fphar.2021.703279 |
work_keys_str_mv | AT hlochkarel higherriskofcardiovasculardiseasesinrheumatoidarthritispatientswithoutmethotrexatetreatment AT dosedelmartin higherriskofcardiovasculardiseasesinrheumatoidarthritispatientswithoutmethotrexatetreatment AT duintjertebbensjurjen higherriskofcardiovasculardiseasesinrheumatoidarthritispatientswithoutmethotrexatetreatment AT zaloudkovalenka higherriskofcardiovasculardiseasesinrheumatoidarthritispatientswithoutmethotrexatetreatment AT medkovahelena higherriskofcardiovasculardiseasesinrheumatoidarthritispatientswithoutmethotrexatetreatment AT vlcekjiri higherriskofcardiovasculardiseasesinrheumatoidarthritispatientswithoutmethotrexatetreatment AT soukuptomas higherriskofcardiovasculardiseasesinrheumatoidarthritispatientswithoutmethotrexatetreatment AT pavekpetr higherriskofcardiovasculardiseasesinrheumatoidarthritispatientswithoutmethotrexatetreatment |